Challenges in Tumor Diagnostics
For decades, tumor diagnostics have relied on methods that are slow, costly, and often imprecise, creating significant challenges for clinicians and devastating consequences for patients.
These limitations are especially pronounced in aggressive cancers like glioblastoma, where delays can close the window for early interventions and inaccuracies can lead to ineffective or harmful treatments.
TumorQ positions itself as a response to these gaps through QCNN-powered analytics aimed at stronger accuracy, faster interpretation, and more adaptable treatment guidance.
Journey Behind TumorQ
TumorQ's origin story is deeply personal. Michelle L. Wu describes being shaped by family loss, late-stage cancer diagnoses among people close to her, and the emotional cost of delayed diagnoses and ineffective treatments.
Her undergraduate work at UC Riverside, mentorship from experts at institutions including UC Berkeley and MIT, and research exposure through City of Hope helped form the interdisciplinary foundation behind NEXQ's oncology direction.
The article frames TumorQ as a bridge between quantum technology and medical science, with encryption and privacy presented as non-negotiable alongside clinical innovation.
TumorQ's Quantum-Driven Solution
TumorQ uses Quantum Neural Networks to process complex medical datasets with speed and precision, and is built around the BraTS2020 Glioma MRI dataset of more than 5,500 samples.
The article reports a 99.98% baseline accuracy target, tumor segmentation across specific regions, and real-time analytics intended to adapt treatment strategies based on imaging and genomic data.
To protect sensitive information, the article highlights quantum encryption algorithms inspired by NIST as part of the platform's privacy posture.
Mission and Vision
The vision for TumorQ centers on patient-centered care where precision, speed, and compassion work together rather than in tension.
NEXQ positions TumorQ as part of a larger quantum-driven shift in oncology, intended to reduce uncertainty, improve treatment planning, and bring more humanity to cancer care delivery.